Endometriosis

IceCure Medical highlighted its ProSense® liquid‑nitrogen cryoablation system at the CIRSE 2025 Annual Meeting, presenting three independent breast‑cancer studies, a trial on abdominal‑wall endometriosis, and an honorary lecture on breast‑oncology de‑escalation. Hands‑on training attracted strong physician interest, and a dedicated CIRSE focus session underscored growing demand for minimally invasive breast‑cancer treatments. Key data from the PRECICE, ICE3, and endometriosis studies demonstrated safety, significant tumor reduction, and pain relief, supporting ProSense®’s role as a cost‑effective, office‑based alternative to surgery and positioning IceCure for expanded global adoption.